Company intelligence / Profile preview
Epirium Bio
San Diego, -California-, United Statesepirium.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Epirium Bio has initiated dosing in a Phase 1 dose-escalation trial of MF-300, a first-in-class oral inhibitor of the enzyme 15-PGDH aimed at treating sarcopenia. The therapy leverages a novel mechanism to enhance muscle regeneration and mitochondrial function. Preclinical data also support potential applications in neuromuscular diseases like spinal muscular atrophy and fibrotic conditions such as IPF.
- Therapeutic areas
- OtherPulmonologyRare DiseasesNeurology
- Modalities
- Orally bioavailable small molecules
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Epirium Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Epirium Bio.